Impact of Bebtelovimab Treatment Timing on COVID‐19 Outcomes in Ambulatory Solid Organ Transplant Recipients
Transplant Infectious Disease · 2025
DOI: 10.1111/tid.14405 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Sonsoles Salto-Alejandre und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Johns Hopkins University, Baltimore, USA. Hauptthemen laut MEDLINE: Organ Transplantation, COVID-19, Transplant Recipients, COVID-19 Drug Treatment. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, Fulbright Grant 2022-2023 to Sonsoles Salto-Alejandre, NHLBI to Mary Grace Bowring.
Abstract (Originalsprache)
Background
Outcomes after bebtelovimab treatment for COVID‐19 were favorable for most but not all solid organ transplant recipients (SOTRs) during the era of Omicron BA.2 to BA.5, but effects of timing of bebtelovimab administration on these outcomes are unknown. We sought to compare outcomes of SOTR who received early bebtelovimab (“EBT”, given ≤ 2 days from diagnosis) versus late bebtelovimab (“LBT”, given between Days 3 and 7), versus no bebtelovimab (NBT).
Methods
This was a retrospective cohort study of SOTRs with mild‐to‐moderate COVID‐19, with endpoint of 30‐day COVID‐19‐related hospitalization. Multivariable logistic regression was performed to determine variables associated with receiving EBT, and to assess impact of EBT on hospitalization. A propensity score (PS) was calculated for EBT versus NBT.
Results
Of 297 SOTRs, 162 (58.1%) received EBT, 46 (16.5%) LBT, and 71 (25.4%) NBT. Early bebtelovimab treatment was associated with a lower risk of 30‐day COVID‐19‐related hospitalization compared to NBT (OR, 0.112 [95% CI, 0.018–0.686]; p = 0.018). There was no significant difference in hospitalization risk between LBT and NBT, suggesting that delayed administration may not confer additional benefits over no treatment.
Conclusions
Early bebtelovimab treatment in outpatient SOTRs was associated with a lower risk of hospitalization compared to no treatment, while late administration did not show a significant advantage over no treatment. Although bebtelovimab is no longer authorized, these findings suggest that the timing of COVID therapies for SOTRs may be important to optimize outcomes. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Infectious Diseases, Johns Hopkins University, Baltimore, USA.
- Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Instituto de Biomedicina de Sevilla (IBiS), Virgen del Rocío University Hospital/CSIC/University of Seville, CIBER de Enfermedades Infecciosas, Instit…
- Comprehensive Transplant Center, Baltimore, USA.
- School of Medicine, Johns Hopkins University, Baltimore, USA.
ORCID-Profile: Sonsoles Salto-Alejandre, Zishan Siddiqui, Julie Langlee, Ishaan Gupta, Mary Grace Bowring, Daniel C Brennan, William Werbel, Robin K Avery
Förderung
- NHLBI NIH HHS
- Fulbright Grant 2022-2023 to Sonsoles Salto-Alejandre
- NHLBI to Mary Grace Bowring
- IMFAHE-University Excellence Fellowship 2021 to Sonsoles Salto-Alejandre
Zitieren
APA
Salto-Alejandre, S., Cochran, W., Siddiqui, Z., Langlee, J., Boyer, L., Freed, K., Purekal, S., Gupta, I., Bowring, M. G., Brennan, D. C., Werbel, W., & Avery, R. K. (2025). Impact of Bebtelovimab Treatment Timing on COVID‐19 Outcomes in Ambulatory Solid Organ Transplant Recipients. Transplant Infectious Disease. https://doi.org/10.1111/tid.14405
Vancouver
Salto-Alejandre S, Cochran W, Siddiqui Z, Langlee J, Boyer L, Freed K, et al. Impact of Bebtelovimab Treatment Timing on COVID‐19 Outcomes in Ambulatory Solid Organ Transplant Recipients. Transplant Infectious Disease. 2025. doi:10.1111/tid.14405
BibTeX
@article{SaltoAlejandre2025,
author = {Salto-Alejandre, Sonsoles and Cochran, Willa and Siddiqui, Zishan and Langlee, Julie and Boyer, Lauren and Freed, Kristin and Purekal, Sophia and Gupta, Ishaan and Bowring, Mary Grace and Brennan, Daniel C and Werbel, William and Avery, Robin K},
title = {Impact of Bebtelovimab Treatment Timing on COVID‐19 Outcomes in Ambulatory Solid Organ Transplant Recipients},
journal = {Transplant Infectious Disease},
year = {2025},
doi = {10.1111/tid.14405}
}
EUVIMED